Theranos: Elizabeth Holmes denies misleading investors

Theranos founder Elizabeth Holmes has denied making misleading statements about the blood-testing startup during cross-examination, as her testimony in defence against fraud charges nears its end.

Former Theranos investors have testified at the trial that Holmes led them to believe the company’s technology was being used by the United States military in the field. Under questioning from prosecutor Robert Leach, Holmes said on Tuesday she never made such statements to investors and that they would not have been true.

Holmes rose to fame in Silicon Valley for her ambitious play to reinvent diagnostic testing. But she has been on trial for three months in a San Jose, California, court, accused of exaggerating Theranos’s technology to bilk patients and investors.

Once valued at $9bn, Theranos collapsed after the Wall Street Journal published a series of articles, starting in 2015, that suggested its devices were flawed and inaccurate.

On the stand, Holmes has testified that she believed Theranos could have achieved its goal of a miniaturised device that would make blood testing cheaper and more accessible.

Holmes has explained some of her actions, such as attempts to quash a Wall Street Journal story on Theranos, saying they were aimed at protecting the company’s trade secrets.

Leach has said he will question Holmes on that claim, which she also used to justify withholding Theranos’s use of third-party blood testing machines from Walgreens.

The pharmacy chain had a partnership with Theranos to offer blood tests in some of its stores.

Holmes’s lawyer has said her defence case is expected to conclude this week.